Saturday 7 November 2026 Export RARE’s income statement to Excel — free account

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024.

Revenue: +8.13%
EPS: +36.2%
Free cash flow: +12.5%

Quarter to September 2026, against a year earlier

Revenue growth 5 yrs

15.49 0.08 −0.51%

Follow RARE

Alert me

Market cap: $1.5B
P/E: 0.0×
Fwd P/E: −4.9×
Dividend yield: —
F-score: 5/9
Altman Z: −3.57
Beneish M: −2.68
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Sold, $m 3.81

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	1	1	8	1	3	3	1	2	2	1	—

Insider Ownership 11.67%

Capital & Financial Ratios $m

Size

Market Cap 1,540.00

Revenue ttm 730.00

Net income ttm (524.00)

Free cash flow ttm (447.00)

Net debt Q (266.00)

Valuation

P/E 0.00

Forward P/E (4.87)

Price / sales 2.17

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.00

Financial health

Current ratio Q 1.40

Debt / equity Q 0.00

Interest coverage Q (5.50)

Growth

Revenue growth Q +8.13%

Operating income growth Q +35.67%

EPS, this year +21.43%

EPS, next year A +108.89%

Revenue, next year A +12.94%

EPS, past 5 yrs —

EPS, next 5 yrs A +71.02%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.31%

10-year low 10-year high

EV/Sales against its own 10 years 1.44%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	577	610	680	266
Receivables	73	122	158	166
Inventory	34	45	52	59
Other	—	—	—	—
	732	817	951	544

	2023	2024	2025	Q'26
Payables	42	39	31	45
ST’ Debt	—	—	—	—
Other	29	54	76	102
	280	344	384	389

Compound Annual Growth %

	10y	5y	3y
Sales	—	19.95%	22.81%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −1.15 Actual −1.16

−2.24 −1.37 −0.49 0.39 1.27

Q4 FY25 Miss −0.09

Q1 FY26 Miss −0.29

Q2 FY26 Beat +0.37

Q3 FY26 Miss −0.01

Q4 FY26 — Feb 11

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY25	−1.20	−1.29	Miss by 0.09
Q1 FY26	−1.55	−1.84	Miss by 0.29
Q2 FY26	−1.27	−0.90	Beat by 0.37
Q3 FY26	−1.15	−1.16	Miss by 0.01
Q4 FY26	0.86	—	Reports 11 February 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.84)	(0.90)	(1.16)	—	—
’25	(1.57)	(1.17)	(1.81)	(1.29)	(5.83)
’24	(2.03)	(1.52)	(1.40)	(1.39)	(6.29)
’23	(2.33)	(2.25)	(2.23)	(1.52)	(8.25)
’22	(2.19)	(2.26)	(3.50)	(2.16)	(10.12)
’21	(2.03)	(1.81)	(1.08)	(1.79)	(6.70)
’20	(2.05)	0.41	(1.13)	(0.37)	(3.07)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	136	214	173	—	—
’25	139	167	160	207	673
’24	109	147	139	165	560
’23	100	108	98	127	434
’22	80	89	91	103	363
’21	99	87	82	83	351
’20	36	62	81	92	271

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(197)	(97)	(43)	—	—
’25	(166)	(109)	(91)	(100)	(466)
’24	(191)	(77)	(67)	(79)	(414)
’23	(157)	(116)	(118)	(84)	(475)
’22	(118)	(77)	(95)	(90)	(380)
’21	(159)	(65)	(60)	(54)	(339)
’20	(95)	87	(62)	(62)	(132)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(203)	(98)	(45)	—	—
’25	(182)	(112)	(92)	(101)	(487)
’24	(204)	(81)	(69)	(80)	(434)
’23	(182)	(133)	(122)	(86)	(522)
’22	(180)	(108)	(121)	(117)	(527)
’21	(176)	(85)	(80)	(70)	(412)
’20	(109)	83	(66)	(84)	(176)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	0	3	51	104	271	351	363	434	560	673	730		+158.0%	760	997	1,169	+20.2%
	Gross margin, %	100.00	99.96	97.77	91.31	97.74	95.44	92.21	89.63	86.25	83.80	82.88		(16.2) pt	Powerpack Ultragenyx Pharmaceutical Inc.’s next three years, line by line Analysts expect revenue to grow 20.2% a year to 2028 — slower than the 158.0% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(246)	(318)	(197)	(399)	(185)	(453)	(702)	(609)	(567)	(571)	(530)		+9.8%
	EBT margin, %	(184,841.35)	(12,187.52)	(382.75)	(385.14)	(68.39)	(128.91)	(193.14)	(140.32)	(101.25)	(84.84)	(72.60)		+184,756.5 pt
	Net income	(246)	(302)	(198)	(403)	(187)	(454)	(707)	(607)	(569)	(575)	(524)		+9.9%
Per share, $
Per share, $	Revenue	0.00	0.06	1.03	1.83	4.45	5.18	5.20	5.90	6.19	6.83	7.15		+132.8%
	Earnings	(6.21)	(7.12)	(3.97)	(7.12)	(3.07)	(6.70)	(10.12)	(8.25)	(6.29)	(5.83)	(5.19)		(0.7%)
	Cash flow	(4.07)	(5.98)	(5.84)	(6.10)	(2.17)	(5.00)	(5.44)	(6.46)	(4.57)	(4.73)	(4.28)		+1.7%
	Capex	(0.26)	(0.07)	(0.08)	(0.44)	(0.72)	(1.08)	(2.09)	(0.64)	(0.22)	(0.21)	(0.10)		(2.1%)
	Free cash flow	(4.32)	(6.05)	(5.92)	(6.54)	(2.89)	(6.07)	(7.53)	(7.10)	(4.80)	(4.94)	(4.38)		+1.5%
	Book value	11.97	9.03	12.23	11.56	18.97	13.61	5.04	3.75	2.82	(0.81)	(3.68)		n/m
	Shares, m	40	42	50	57	61	68	70	74	91	99	101		+10.7%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	0.00	767.05	42.03	23.30	31.08	16.22	8.76	8.16	6.80	3.37	2.17		90.7
	P/B	5.84	5.46	3.55	3.70	7.30	6.18	9.03	12.86	14.93	0.00	0.00		6.9
	EV/Sales	0.00	681.09	33.10	16.02	26.64	14.12	6.70	6.83	5.71	2.36	1.80		79.3
	EV/FCF	(13.95)	(7.24)	(5.78)	(4.49)	(41.00)	(12.05)	(4.62)	(5.68)	(7.37)	(3.26)	(2.94)		(10.5)
Cash, $m
Cash, $m	Operating cash flow	(161)	(254)	(291)	(345)	(132)	(339)	(380)	(475)	(414)	(466)	(437)		+12.5%
	Capex	(10)	(3)	(4)	(25)	(44)	(73)	(146)	(47)	(20)	(21)	(10)		+8.4%
	Free cash flow	(171)	(257)	(295)	(370)	(176)	(412)	(527)	(522)	(434)	(487)	(447)		+12.3%
Balance, $m
Balance, $m	Working capital	341	199	448	748	1,106	675	623	452	473	567	155		+5.8%
	Net debt	(382)	(234)	(460)	(755)	(1,202)	(740)	(748)	(577)	(610)	(680)	(266)		+6.6%
	Shareholders’ equity	474	383	609	654	1,154	923	352	275	255	(80)	(376)		n/m
Returns, %
Returns, %	ROA	(44.70)	(58.59)	(32.65)	(43.42)	(12.89)	(27.67)	(46.12)	(39.98)	(38.01)	(37.89)	(44.08)		+6.8 pt
	ROIC	(167.73)	(138.02)	(155.57)	0.00	0.00	(130.83)	0.00	0.00	0.00	0.00	0.00		+167.7 pt
	ROE	(48.93)	(70.48)	(39.83)	(63.79)	(20.64)	(43.72)	(110.96)	(193.34)	(214.55)	(657.14)	285.68		(608.2) pt
People
People	Employees	376	520	610	740	893	1,119	1,311	1,276	1,294	1,371	—		+15.5%
	Revenue/emp, $m	0.00	0.01	0.08	0.14	0.30	0.31	0.28	0.34	0.43	0.49	—		+123.4%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ABSI Absci Corporation	$1.6B	— (loss-making)	— (loss-making)	−46.37% (below 0%: shrinking)	n/m	−71.74% (below 0%: shrinking)	100.00%	(10,741.51%)	Compare
SLS SELLAS Life Sciences Group, Inc.	$1.6B	— (loss-making)	— (loss-making)	−57.10% (below 0%: shrinking)	n/m	−3.52% (below 0%: shrinking)	0.00%	0.00%	Compare
KLRA Kailera Therapeutics, Inc.	$1.6B	— (loss-making)	—	—	n/m	−325.95% (below 0%: shrinking)	—	0.00%	Compare
BRVE Braveheart Bio, Inc.	$1.6B	—	—	—	n/m	—	—	0.00%	Compare
NTLA Intellia Therapeutics, Inc.	$1.6B	— (loss-making)	— (loss-making)	−48.03% (below 0%: shrinking)	n/m	−11.05% (below 0%: shrinking)	100.00%	(1,707.73%)	Compare
RARE Ultragenyx Pharmaceutical Inc.	$1.5B	— (loss-making)	— (loss-making)	+8.13% (above 0%: growing)	n/m	+12.50% (above 0%: growing)	81.50%	(63.58%)
NBTX Nanobiotix S.A. - Sponsored ADR	$1.5B	— (loss-making)	—	−71.69% (below 0%: shrinking)	n/m	−177.26% (below 0%: shrinking)	0.00%	0.00%	Compare
PGEN Precigen, Inc.	$1.5B	60.3×	20.8×	+2,437.58% (above 0%: growing)	n/m	+140.34% (above 0%: growing)	91.22%	52.13%	Compare
NUVB Nuvation Bio Inc.	$1.5B	— (loss-making)	— (loss-making)	+242.61% (above 0%: growing)	n/m	+34.07% (above 0%: growing)	73.46%	(93.90%)	Compare
Median of peers	$1.6B	—	—	−47.20%	—	−11.05%	82.34%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 27 March 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	11.41m	(1.29m)	17.00
2024	13.72m	8.19m	30.00
2023	13.08m	11.29m	35.00
2022	12.14m	3.31m	33.00
2021	9.52m	(2.15m)	61.00

Ownership

Directors and executive officers, together 5.20%

The Vanguard Group 8.80%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Ultragenyx Pharmaceutical Inc. (RARE) Latest News

6 Nov

Impact 3 · 3:30 AM · GlobeNewswire

Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

5 Nov

Impact 4 · 12:03 PM · GuruFocus.com

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy Launches, ...

4 Nov

Impact 4 · 10:29 AM · The Motley Fool transcript

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Impact 4 · 8:30 AM · Moby

Ultragenyx Pharmaceutical Inc. Q3 2026 Earnings Call Summary

Impact 4 · 8:10 AM · Simply Wall St.

Gene Therapy Launches Could Be A Game Changer For Ultragenyx Stock (RARE)

Impact 4 · 6:14 AM · Simply Wall St.

Ultragenyx Pharmaceutical (RARE) Recasts The Story After FDA Approvals As Valuation Debate Builds

3 Nov

Impact 4 · 9:14 PM · MarketBeat transcript

What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call

Impact 4 · 4:01 PM · GlobeNewswire

Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027

30 Oct

Impact 3 · 5:53 PM · Insider Monkey

Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?

27 Oct

Impact 3 · 4:05 PM · GlobeNewswire

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

Impact 3 · 9:00 AM · Zacks

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

15 Oct

Impact 4 · 9:33 AM

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

14 Oct

Impact 4 · 9:30 AM · Zacks

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

Impact 4 · 8:30 AM · GlobeNewswire

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

8 Oct

Impact 4 · 9:49 AM · Zacks

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

Impact 3 · 6:08 AM · Simply Wall St.

Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy?

7 Oct

Impact 4 · 12:00 PM · Proactive Investors

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

Impact 4 · 8:30 AM · GlobeNewswire

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

Impact 3 · 11:51 AM · Stocktwits

Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity

6 Oct

Impact 3 · 8:16 PM · Simply Wall St.

Ultragenyx (RARE) EMA Validation of MPS IIIA Gene Therapy: Inflection Point or Incremental Milestone?

5 Oct

Impact 4 · 10:46 AM · Zacks

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

2 Oct

Impact 4 · 2:00 AM

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

22 Sep

Impact 4 · 3:09 PM · Stocktwits

RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results

Impact 4 · 6:18 AM · Insider Monkey

FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?

19 Sep

Impact 5 · 10:10 AM

How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI

18 Sep

Impact 5 · 10:49 AM

RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy

Impact 4 · 8:16 AM · Stocktwits

Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy

Impact 4 · 8:00 AM

Andelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following FDA Approval of Ultragenyx's FAYUVITM to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Impact 4 · 7:30 AM

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Impact 4 · 6:24 AM · biopharmadive.com

Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug

Ultragenyx Pharmaceutical Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Ultragenyx Pharmaceutical Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 27 March 2026

Chief executive’s pay

Ownership

Ultragenyx Pharmaceutical Inc. (RARE) Latest News

6 Nov

5 Nov

4 Nov

3 Nov

30 Oct

27 Oct

15 Oct

14 Oct

8 Oct

7 Oct

6 Oct

5 Oct

2 Oct

22 Sep

19 Sep

18 Sep

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Ultragenyx Pharmaceutical Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 27 March 2026

Chief executive’s pay

Ownership

Ultragenyx Pharmaceutical Inc. (RARE) Latest News

6 Nov

5 Nov

4 Nov

3 Nov

30 Oct

27 Oct

15 Oct

14 Oct

8 Oct

7 Oct

6 Oct

5 Oct

2 Oct

22 Sep

19 Sep

18 Sep

Stockrow Weekly